Asset Class

Formation Bio's $600 Million Accelerator Fund: How an AI-Native Pharma Company Is Turning Drug Development Into an Asset Class

Formation Bio has launched a $600 million fund to acquire individual clinical-stage drug assets, housing each in a separate entity while developing them through a unified, AI-driven organization. This novel approach aims to transform drug development into an investable asset class by addressing the post-discovery bottleneck.